Augmenting Performance Status: A Preliminary Study of Objective Kinematic Assessment Using Motion Capture [0.03%]
关于动作捕捉客观动态评估的初步研究——增强功能状态评估体系的研究
Christopher Wang,Ajay Prasad,Elizabeth Qi et al.
Christopher Wang et al.
Introduction: Understanding performance status (PS) is an essential aspect of oncologic care. PS is traditionally evaluated using the Karnofsky Performance Status (KPS) or Eastern Cooperative Oncology Group (ECOG) perform...
Treatment Sequencing and Immunotherapy Rechallenge in Advanced Non-Small-Cell Lung Cancer: Final 24-Month Real-World Results from the French LIST Study [0.03%]
法国LIST研究的最终24个月真实世界结果：晚期非小细胞肺癌的治疗顺序和免疫治疗再挑战疗法
Benoît Godbert,Elisa Gobbini,Yaacoub Khalife et al.
Benoît Godbert et al.
Introduction: Nivolumab is approved for the treatment of advanced non-small cell lung cancer (aNSCLC) after prior chemotherapy. The Lung Initiative on Sequence Therapy (LIST) study evaluated long-term outcomes, safety and...
Occupational Variation in the Incidence of Laryngeal Cancer in the Nordic Countries [0.03%]
nordic各国职业性喉癌发病差异研究
Timo Carpén,Zakarya Hadj-Allal,Rayan Nikkilä et al.
Timo Carpén et al.
Introduction: Laryngeal cancer (LC) constitutes almost one third of the head and neck cancers, and its main risk factors, alcohol use and smoking, are well established. Our aim was to explore the variation in the incidenc...
Real-World Description of Non-ICANS Neurologic Events Among Patients with Relapsed or Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel Using Two Large US Databases [0.03%]
基于两个大型美国数据库的复发/难治性多发性骨髓瘤患者使用Ciltacabtagene autoleucel治疗后出现非ICANS神经系统事件的真实世界特征描述研究
Surbhi Sidana,Saurabh P Nagar,Sabyasachi Ghosh et al.
Surbhi Sidana et al.
Introduction: Ciltacabtagene autoleucel (cilta-cel) is a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy approved in the USA for relapsed or refractory multiple myeloma (RRMM) as early as follo...
Telerehabilitation for Pain, Function, and Quality of Life in Patients with Cancer: A Systematic Review [0.03%]
癌症患者的疼痛、功能和生活质量的远程康复治疗：一项系统综述
Leidy Tatiana Ordoñez-Mora,Diana Carolina Urrea-Arango,Juan Carlos Avila-Valencia et al.
Leidy Tatiana Ordoñez-Mora et al.
Introduction: Cancer rehabilitation improves function, quality of life, and symptom control, yet access to specialized programs is limited by geographic, financial, and systemic barriers. Telerehabilitation has emerged as...
Radiopharmaceutical Therapy in Oncology: Perspectives from Transatlantic Experts [0.03%]
肿瘤学放射药物治疗：东西方专家视角
Désirée Deandreis,Heather Jacene,Patrick Therasse et al.
Désirée Deandreis et al.
Radiopharmaceutical therapy (RPT), the administration of a radioactive element coupled with a targeting vector, is one of the most promising innovations in oncology, supported by clinical trials. A theranostic approach-the pairing of diagno...
Results from a Pilot Study of HyBryte™ (Topical Synthetic Hypericin) Versus Valchlor® (Mechlorethamine) in the Treatment of CTCL [0.03%]
HyBryte™（外用合成 hypericin）与 Valchlor®（氯-etronium）治疗CTCL的初步研究结果
Brian Poligone,Christopher Pullion,Adam Rumage et al.
Brian Poligone et al.
Introduction: Mycosis fungoides (MF) is the most common type of primary cutaneous T-cell lymphoma (CTCL), a malignant and chronic skin disease. Early-stage MF has a generally favorable prognosis, but effective and well-to...
Real-World Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Receiving Teclistamab: A Panel Chart Review Study [0.03%]
替西扎马b治疗复发/难治多发性骨髓瘤患者的现实世界特征、治疗模式和临床结局：分板图表审核研究
Binod Dhakal,Moshe Y Levy,Gilbert Ko et al.
Binod Dhakal et al.
Introduction: Teclistamab is an established standard of care for the treatment of relapsed/refractory multiple myeloma (RRMM) based on MajesTEC-1 study results. United States (US)-based real-world studies of teclistamab t...
Burden of Disease, Treatment Patterns, and Healthcare Resource Utilization in Multiple Myeloma in the Middle East and North Africa Region: A Targeted Literature Review [0.03%]
中东和北非地区多发性骨髓瘤的疾病负担、治疗模式和卫生资源利用：定向文献回顾
Meral Beksac,Mohamed Samra,Omar Abduljalil et al.
Meral Beksac et al.
Globally, the multiple myeloma (MM) landscape varies widely, with incidence, treatment patterns, outcomes, and healthcare resource utilization (HCRU) differing across countries and regions. Many factors contribute to these differences, incl...
First-Line Tislelizumab Plus Chemotherapy for Advanced or Metastatic Squamous Non-Small Cell Lung Cancer: 4-Year Long-Term Follow-Up from RATIONALE-307 [0.03%]
替雷利珠单抗联合化疗用于晚期或转移性鳞状非小细胞肺癌一线治疗：RATIONALE-307研究的四年长期随访数据
Zhijie Wang,Xinmin Yu,Jun Zhao et al.
Zhijie Wang et al.
Introduction: Squamous nonsmall cell lung cancer (sq-NSCLC) is challenging to treat, with shorter survival when compared with other NSCLC subtypes. Tislelizumab has demonstrated efficacy when combined with chemotherapy fo...